Search

Author/Creator Pike, M.

4. Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study. Issue 4 (24th March 2016)

Authors:
Wallace, D. J.; Hobbs, K.; Clowse, M. E. B.; Petri, M.; Strand, V.; Pike, M.; Merrill, J. T.; Leszczyński, P.; Neuwelt, C. M.; Jeka, S.; Houssiau, F.; Keiserman, M.; Ordi‐Ros, J.; Bongardt, S.; Kilgallen, B.; Galateanu, C.; Kalunian, K.; Furie, R.; Gordon, C.
Journal:
Arthritis care & research
Issue:
Volume 68:Issue 4(2016:Apr.)
Page Start:
534
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. THU0277 Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008). (23rd January 2014)

Authors:
Wallace, D. J.; Ordi-Ros, J.; Neuwelt, M.; Kalunian, K.; Kilgallen, B.; Bongardt, S.; Petri, M.; Pike, M.; Jeka, S.; Gordon, C.; Strand, V.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 72:Supplement 3(2013)
Page Start:
A259
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗